Conformance to Evidence-Based Treatment Recommendations in Schizophrenia Treatment Services
Dear Editor:
Addington et al 1 report a high level of conformance to pharmacologic recommendations of the 2003 Schizophrenia Patient Outcomes Research Team (PORT) guidelines in the clinical care provided to a sample of outpatients with schizophrenia. 2 I was surprised, however, that a number of important aspects were not captured in their criteria for quality care.
Managing adverse effects of antipsychotics is a crucial component of prudent care. Patients in this study were shown to receive diligent monitoring for extrapyramidal symptoms, but the adequacy of management of metabolic and other important antipsychotic side effects was not reported.
I also wonder if more flexible criteria for antipsychotic prescribing could have provided a more meaningful assessment of care in some cases. Although the average patient is best treated by average doses, individual patients can vary widely in their medication responses and preferences. Addington et al 1 only accepted antipsychotic dosages of 300 to 600 chlorpromazine equivalents per day; however, departure from these dosing recommendations may represent the most appropriate care for some, given the substantial pharmacokinetic and pharmacodynamic variability that can exist between people. I am unsure why Addington et al 1 operationalized the PORT pharmacological recommendations with fairly minimal attention to side-effect management and without acknowledging interpatient variability in responses to antipsychotics, especially considering that the guidelines themselves address these issues. The 2003 PORT guidelines 2 state that "choice of antipsychotic therapy should be guided by consideration of individual patient and treatment-related factors that may influence treatment outcomes," p196 in which side effects, therapeutic responses, and patient preferences are included. The guideline authors also acknowledge that "a substantial proportion of persons (up to 50%) can be maintained successfully at these lower doses [less than 300 chlorpromazine equivalents per day], warranting a gradual and carefully monitored effort to reduce dosage over time." p 198 Rather than suggesting strict conformance to dosing recommendations, the guidelines recognize interpatient variability and recommend instead that "reasons for dosages outside of this range should be documented." p 196 Perhaps these points would be more appropriately directed to the authors of the earlier US study 3 to which Addington et al 1 originally intended to compare their findings. Nevertheless, a more thorough discussion of the above limitations may have clarified whether the true strength of the article by Addington et al lies more in its ability to compare trends in clinical care across different sites or in its ability to comment fairly on the actual quality of care being provided to their sample of patients with schizophrenia.
Nathan Unger, MD Vancouver, British Columbia
Reply..
Re: Conformance to Evidence-Based Treatment Recommendations in Schizophrenia Treatment Services

Dear Editor:
Dr Unger has raised some pertinent questions about our study of conformance to evidence-based treatment recommendations. 1 I agree with Dr Unger that a number of important criteria for quality care were not captured, but it was not the intention of this study to conduct a comprehensive assessment of all components of care. As we indicated in the paper, we chose the PORT framework to enhance the generalizability of our findings by making comparisons with published data. We have recently published a more comprehensive framework for assessing the performance of schizophrenia services. 2 The most significant comment in this letter lies in the last sentence in which the author raises 2 issues, fairness and measurement of quality of care. We are aware that clinicians' perception of the process, motives, and purposes of performance measurement is one of several important factors that facilitate or block implementation of performance measurement. 3 This perception is also affected by the qualities of individual performance measures, such as the evidence base and the degree of control over the measure. Despite Dr Unger's comments about polypharmacy and high doses, the evidence base for that measure, as indicated by a recent review, 4 is clear, and the control lies to a significant degree with the clinician.
The perception of fairness also requires a sense of agency in the design of the process of evaluation and of how the results might be used. For example, we know that a recent study 5 demonstrated that 60% of patients can be successfully switched from polypharmacy to monotherapy. This suggests that a reasonable target for improvement would be to reduce the polypharmacy rate by 40% to 50%. Clinicians are more likely to buy into a process if they contribute to the design of the process, if the outcome is to improve the quality of care, and if the process is seen as nonjudgemental. 3 Our study 1 accurately demonstrated high-quality care on the measures of pharmacotherapy, for which the clinicians can take credit. We also pointed out one area of pharmacotherapy for possible improvement and would challenge Dr Unger and other psychiatrists to become engaged in improving that component of care.
